Immuron Ltd Stock Price, News & Analysis

Immuron Limited (ASX: IMC; NASDAQ: IMRN) has appointed Paul Brennan as an independent Non-Executive Director, effective March 16, 2022. Brennan's extensive healthcare experience includes his role as CEO of PolyNovo Limited, where he grew the company significantly. His appointment is expected to leverage Immuron's unique intellectual property in gut health and enhance its clinical research capabilities. Non-Executive Chairman Dr. Roger Aston expressed confidence in Brennan's diverse background, which includes technology commercialization and international marketing.

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical firm, has successfully claimed a cash refund of AUD $306,154 under the Australian Government’s Research and Development Income Tax Concession program. This refund pertains to eligible research and development expenses from the 2021 Financial Year. The company is committed to developing oral immunotherapeutics for gut-mediated pathogens.

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, has received a European Patent for treating travelers' diarrhea. The patent, granted on January 5, 2022, covers 'Composition and method for the treatment and prevention of enteric bacterial infections.' This extends Immuron's patent coverage across multiple regions, including Australia, India, Canada, and the US. Given the rising antibiotic resistance in enteric pathogens, this patent validates a preventative approach that addresses a critical health issue prevalent among travelers and military personnel.

Immuron Limited has secured AU $4.8 million (USD $3.43 million) from the U.S. Department of Defense for its product Travelan. Additionally, the company received AU $1.4 million (USD $1.02 million) from the U.S. Naval Medical Research Center to support Travelan's clinical development. The total funding of AU $6.2 million (USD $4.45 million) will be used to test a single larger dosing regimen for military applications. A clinical trial involving 60 volunteers will assess the efficacy of Travelan against Enterotoxigenic Escherichia coli.

Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced a clinical trial program to evaluate the efficacy of Travelan® and two non-antibiotic OTC products for Travelers' Diarrhea. The Uniformed Services University (USU) commenced manufacturing investigational products in November 2021, anticipating enrollment to start in April 2022. The trial aims to enroll 1,336 participants over 18 months, assessing three nutraceuticals against a placebo. This initiative involves collaboration with USU’s Infectious Diseases Clinical Research Program and other organizations to enhance health strategies for travel risk.

Immuron Limited has announced the successful completion of its investigational medical product manufacturing for the US Naval Medical Research Centre (NMRC) after a year-long hiatus due to COVID-19. The company plans to submit an IND application to the U.S. FDA in Q1 2022 to initiate two human Phase II trials. One trial aims to prevent infectious diarrhea caused by ETEC, while the second focuses on campylobacteriosis. Both trials will take place at Johns Hopkins Bloomberg School of Public Health, with the first expected to commence in H1 2022.

Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced a significant advancement in its antiviral research with the publication of findings regarding its product IMM-124E. Conducted by Hadassah Medical Center, the study, titled Augmented antiviral T cell immunity by oral administration of IMM-124E, outlines results from a preclinical mouse model and a phase I/IIa clinical trial. The research indicated that IMM-124E promotes antiviral T cell responses against various viral strains, including SARS-CoV-2 and Hepatitis B. The company has also filed an international patent application for IMM-124E.

Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced the resignation of Peter Anastasiou, effective immediately. Anastasiou, who joined the Board in 2015 and served as Vice Executive Chairman, cited the missed opportunity to invest in a significant Covid vaccine asset as a reason for his departure. Despite this, he expressed confidence in the company's technology and financial standing. The Board commended Anastasiou for his contributions, stating that the company has a strong cash reserve and an exciting project pipeline.

Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced the termination of its proposed acquisition of a private biotechnology firm focused on vaccine development due to ASX regulatory concerns. The planned acquisition, aimed at enhancing shareholder value and providing a COVID-19 vaccine candidate, was deemed infeasible as the ASX did not find sufficient information to meet its listing requirements. Consequently, Immuron will resume trading from September 24, 2021, and incur approximately $450k in professional fees related to this unsuccessful endeavor.